← FDA DRUG APPROVALS

FDA ANDA · ANDA206557

SIMVASTATIN

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA206557
TYPE
ANDA
ORIGINAL APPROVAL
2017-11-13
LATEST ACTION
2023-10-27
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SIMVASTATINPrescription
SIMVASTATIN 20MG · TABLET · ORAL
SIMVASTATINPrescription
SIMVASTATIN 5MG · TABLET · ORAL
SIMVASTATINPrescription
SIMVASTATIN 40MG · TABLET · ORAL
SIMVASTATINPrescription
SIMVASTATIN 10MG · TABLET · ORAL
SIMVASTATINPrescription
SIMVASTATIN 80MG · TABLET · ORAL

Approval history

2023-10-27Labeling · Supplement 5 · standardAP
2023-10-27Labeling · Supplement 6 · standardAP
2023-10-27Labeling · Supplement 7 · standardAP
2020-05-14Labeling · Supplement 4 · standardAP
2019-07-30Labeling · Supplement 3 · standardAP
2019-07-30Labeling · Supplement 1 · standardAP
2017-11-13UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →